ストックスクリーナーアプリを入手
13.16
0.15%
-0.02
アフターアワーズ：
13.16
Oric Pharmaceuticals Inc (ORIC) 最新ニュース
1,078,055 Shares of Oric Pharmaceuticals, Inc. $ORIC Purchased by Bank of America Corp DE - MarketBeat
ORIC Pharmaceuticals CFO Dominic Piscitelli Sells 600 Shares of ORIC Stock - GuruFocus
Oric Pharmaceuticals CFO Dominic Piscitelli sells $8,102 in shares - Investing.com
Form 4 Oric Pharmaceuticals Inc For: 25 September By Investing.com - Investing.com Nigeria
A finance chief exercised 600 options and sold 600 shares at Oric Pharmaceuticals (ORIC). - Stock Titan
ORIC Pharmaceuticals stock trades 10.7 percent below its 52-week high - AD HOC NEWS
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpStill a Buy? - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) Coverage Initiated at BTIG Research - MarketBeat
BTIG initiates ORIC Pharmaceuticals stock coverage with buy rating - Investing.com
BTIG initiates ORIC Pharmaceuticals stock coverage with buy rating By Investing.com - Investing.com Canada
BTIG initiates coverage of ORIC Pharmaceuticals with Buy rating, $26 price target - TradingView
ORIC Pharmaceuticals Initiates Coverage by BTIG -- Rating Set to Buy - GuruFocus
(ORIC) Volatility Zones as Tactical Triggers - Stock Traders Daily
ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits
Oric Pharmaceuticals Inc (NYSE: ORIC) Share Price, ORIC Stock News, ORIC Share Price & Updates - kalkine.com.au
We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth - Moomoo
Oric Pharmaceuticals (ORIC) Stock Analysis: A 60% Upside Potential with Strong Buy Ratings in Biotech - DirectorsTalk Interviews
Why ORIC Pharmaceuticals (ORIC) Is Back In The Spotlight - simplywall.st
ORIC Pharmaceuticals Inc. (US68622P1093.SG) stock price, news, quote and history - Yahoo Finance UK
ORIC (ORIC) Doubles Down On Prostate Cancer With Phase 3 Launch - AlphaStreet
ORIC: Advancing late-stage cancer programs with strong safety differentiation and robust financial runway - tradingview.com
Squarepoint Ops LLC Purchases Shares of 344,343 Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Precision Trading with Oric Pharmaceuticals Inc. (ORIC) Risk Zones - Stock Traders Daily
ORIC: Advancing late-stage prostate and lung cancer programs with robust funding and global trials - TradingView
ORIC: Phase III trials and robust funding position support late-stage oncology pipeline growth - TradingView
ORIC Pharmaceuticals at Wells Fargo conference: late-stage pipeline in focus - Investing.com Canada
Oric Pharmaceuticals joins 2026 Cantor Global Healthcare Conference fireside chat: Can ORIC break above $12.51? - Traders Union
ORIC: Advancing late-stage cancer therapies with strong efficacy, safety, and major market potential - TradingView
Enterprise value to revenue forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
Enterprise value to revenue forward of Oric Pharmaceuticals, Inc. – MUN:4TZ - TradingView
ORIC stock holds steady as biotech eyes next trial and earnings - AD HOC NEWS
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Himalayas-1: Bayer and ORIC Double Down on Prostate Cancer With New Phase 3 Combo Trial - TipRanks
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
ORIC stock holds firm as biotech valuation nears 0.93 billion USD - ad-hoc-news.de
(ORIC) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Oric Pharmaceuticals stock holds above $13 as BlackRock boosts stake - ad-hoc-news.de
Oric Pharmaceuticals (NASDAQ: ORIC) CFO sells 77,000 shares - Stock Titan
ORIC Pharmaceuticals (NASDAQ: ORIC) officer plans $3.1M stock sale - Stock Titan
Blue Owl Capital Holdings LP Invests $4.33 Million in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) Sets New 12-Month HighHere's Why - MarketBeat
Oric (ORIC) Earnings Report: EPS Misses Its Estimate in Latest Trading; After Earnings: The Stock Gains 4.04% in the Latest SessionForward EPS Estimate - vinanet.vn
BCAX Stock Price and Chart — NASDAQ:BCAX - TradingView
HC Wainwright Issues Pessimistic Outlook for ORIC Earnings - MarketBeat
Understanding Momentum Shifts in (ORIC) - Stock Traders Daily
ORIC Pharmaceuticals (ORIC) Slips 1.17% as Biotech Stock Approaches Key Support at $12.89Price Target - dars.gov.et
Price to book forward of Oric Pharmaceuticals, Inc. – HAM:4TZ - TradingView
What is HC Wainwright's Forecast for ORIC Q1 Earnings? - MarketBeat
ORIC Pharmaceuticals, Inc. (ORIC) options chain - Yahoo Finance Australia
ORIC PHARMACEUTICALS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $27 FROM $25 - webull.com
ORIC Maintained by HC Wainwright & Co. -- Price Target Raised to $27 - GuruFocus
H.C. Wainwright raises ORIC Pharmaceuticals price target to $27 on pipeline progress - Investing.com
H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Raises Target Price to $27 - Moomoo
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
ORIC Pharmaceuticals (ORIC) Q2 Losses Put Valuation In Focus As Shares Rally - Sahm
Dimensional Fund Advisors LP Boosts Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Is ORIC Pharmaceuticals' (ORIC) Equity-Funded ESOP Masking or Clarifying Its Widening Net Losses? - Yahoo Finance
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):